INTENSIVE VASCULAR TRAINING IN STAGE IIB OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE - THE ADDITIVE EFFECTS OF INTRAVENOUS PROSTAGLANDIN E(1) OR INTRAVENOUS PENTOXIFYLLINE DURING TRAINING

被引:69
作者
SCHEFFLER, P
DELAHAMETTE, D
GROSS, J
MUELLER, H
SCHIEFFER, H
机构
[1] UNIV HOSP SAARLAND, DEPT INTERNAL MED CARDIOL ANGIOL, HOMBURG, GERMANY
[2] REHABIL CLIN, BLIESKASTEL, GERMANY
关键词
CLAUDICATION; EXERCISE; PROSTAGLANDINS; PENTOXIFYLLINE;
D O I
10.1161/01.CIR.90.2.818
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In a randomized open study, the combination of either prostaglandin E(1) (PGE(1)) or pentoxifylline with controlled vascular training was compared with vascular training alone in patients with peripheral arterial occlusive disease in stage IIb. Forty-four patients were randomly assigned to treatment either of intensive vascular training alone (n=15) or in combination with either IV pentoxifylline (200 mg over 2 hours BID, n=15) or PGE, (40 mu g over 2 hours BID, n=14). The basic therapy was a well-defined routine for vascular training, which was identical for all groups. The duration of therapy was 4 weeks. In all three test groups, there was a significant increase in the walking distance. There was a 119% increase in symptom-free walking distance in the exercise-only group. In comparison with exercise alone, the additional administration of pentoxifylline produced no greater effect; the increase was 105%. In contrast, administration of PGE(1) combined with exercise achieved a remarkable improvement of 604%. Between-group comparison revealed the significant superiority of treatment with PGE(1) (P<.05). During the 1-year follow-up, there was a reduction in the walking performance in all groups, albeit of variable extent. In the exercise-only and the pentoxifylline groups, the maintained increase in walking distance was only 30% compared with baseline values before the beginning of therapy. In the PGE(1) group, on the other hand, the maintained improvement was 149%. Nine of 14 patients were still in stage IIa of peripheral arterial occlusive disease 1 year after PGE(1) therapy.
引用
收藏
页码:818 / 822
页数:5
相关论文
共 19 条
  • [1] ANDRIESSEN MPHM, 1989, VASA-J VASCULAR DIS, V18, P63
  • [2] ANDRIESSEN MPHM, 1989, VASA-J VASCULAR DIS, V18, P56
  • [3] Balzer K, 1989, Vasa Suppl, V28, P31
  • [4] Blume J, 1986, PROSTAGLANDIN E1 ATH, P75
  • [5] INTERMITTENT CLAUDICATION - IS A SUPERVISED EXERCISE CLASS WORTH WHILE
    CLIFFORD, PC
    DAVIES, PW
    HAYNE, JA
    BAIRD, RN
    [J]. BRITISH MEDICAL JOURNAL, 1980, 280 (6230) : 1503 - 1505
  • [6] CREUTZIG A, 1988, PROSTAGLANDIN E1 WIR, P95
  • [7] DIEHM C, 1989, VASA-J VASCULAR DIS, P26
  • [8] EHRLY AM, 1987, VASA S, V20, P196
  • [9] EKROTH R, 1978, SURGERY, V84, P640
  • [10] VASOACTIVE DRUGS IN PERIPHERAL ARTERIAL VASCULAR DISORDERS
    HEIDRICH, H
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1985, 110 (31-3) : 1219 - 1224